This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Transcription activator-like effector (TALE) domain nucleases for genome engineering	<p>TALE domain-linked nucleases could be used to modify the human genome to treat genetic diseases. As proof of principle, transfection of a nuclease linked to an engineered TALE domain allowed insertion of a specific sequence into the <i>chemokine receptor 5</i> (<i>CCR5</i>; <i>CD195</i>) gene in up to 16% of alleles. Next steps could include optimizing the delivery and efficiency of TALE domain nucleases.</p> <p>SciBX 4(5); doi:10.1038/scibx.2011.147 Published online Feb. 3, 2011</p>	Patent and licensing status undisclosed	<p>Miller, J.C. <i>et al. Nat. Biotechnol.</i>; published online Dec. 29, 2010; doi:10.1038/nbt.1755</p> <p>Contact: Edward J. Rebar, Sangamo BioSciences Inc., Richmond, Calif. e-mail: erebar@sangamo.com</p>